Erschienen in:
14.07.2020 | ASO Author Reflections
ASO Author Reflections: The De-Escalation of Sentinel Node Biopsy for Breast Cancer
verfasst von:
James Sun, MD, Loretta S. Loftus, MD, Marie Catherine Lee, MD
Erschienen in:
Annals of Surgical Oncology
|
Sonderheft 3/2020
Einloggen, um Zugang zu erhalten
Excerpt
Among clinically node-negative (cN0) breast cancer patients, sentinel lymph node biopsy (SLNB) is the standard of care for surgical axillary staging; however, as with all surgical techniques, it confers risk of injury, especially among elderly patients with multiple comorbidities. It has been previously established that elderly breast cancer patients tend to have more indolent tumors that are hormone responsive and can be adequately treated with hormonal suppression;
1 therefore, SLNB status does not impact management. As such, the Society of Surgical Oncology and Choosing Wisely
® Foundation released guidelines recommending against SLNB for cN0 patients ≥ 70 years of age with hormone receptor-positive invasive breast cancer.
2 …